Status:

WITHDRAWN

Optimizing Microdosing and Meditation

Lead Sponsor:

National University of Natural Medicine

Conditions:

Meditation

Microdosing

Eligibility:

All Genders

21+ years

Phase:

NA

Brief Summary

The goal of this clinical trial is to test the feasibility of combining meditation with psilocybin microdosing in healthy adults. The main questions it aims to answer are: 1. Recruitment and retentio...

Detailed Description

Research has shown that both meditation and high doses of psilocybin can produce enhanced feelings of well-being that persist. When combined, the synergistic effects might be more than the sum of the ...

Eligibility Criteria

Inclusion

  • Age 21 or older - Oregon Psilocybin Services Act sets the minimum eligible age of 21.
  • Able to attend all study events.
  • Able to read and speak fluent English.
  • No more than 100 hours of lifetime meditation experience.
  • No prior experience of microdosing of a psychedelic substance and no more two macrodose experiences.

Exclusion

  • A personal or family history of an immediate family member of schizophrenia, psychosis of any kind, mania, or hypomania.
  • A current prescription for lithium, antipsychotic, Phase II UGT substrate such as diclofenac or probenecid, or an unwillingness to taper off these or other medications that the study clinicians determine to be a risk for interactions.
  • Active suicidal ideations or history of suicide attempts. Passive ideation, such as "I wouldn't mind if I never woke up again" is permissible.
  • Uncontrolled hypertension or heart disease.
  • Any form of personality disorder.
  • Current recreational drug use or any form of substance abuse in the previous six months.
  • Pregnancy, plans to become pregnant during the study period, or breast feeding.
  • Active cancer treatment.
  • Any mental illness that could currently be rated as severe. This includes but is not limited to a PHQ-9 score above 20, GAD-7 score above 14, or their equivalents on comparable scales and acute trauma related symptoms.

Key Trial Info

Start Date :

October 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2025

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT06560658

Start Date

October 1 2024

End Date

November 1 2025

Last Update

June 5 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

National University of Natural Medicine

Portland, Oregon, United States, 97201